Visit the ACCC COVID-19 Resource Center & Listserv for Insights on Providing Optimal Patient Care During the Pandemic.
 
Home / Learn / Immunotherapy / Care Coordination & Communication

Care Coordination & Communication

Members of the ACCC IO Institute Executive Committee discuss why care coordination and communication among the IO team, other providers, and the patient is critical for effective delivery of immunotherapy for cancer. (features Mark Faries, MD; Sanjiv Agarwala, MD; and Niesha Griffith, MS, RPh, FASHP)

 

The Latest Resources

  • [PODCAST] Episode 12: What's Trending in Cancer Care

    Discover the results of the 2019 Trending Now in Cancer Care Survey—what tops the list of challenges, what areas are trending towards growth, and how cancer programs are evolving to meet the demands of 21st-century cancer care delivery.

  • [PODCAST] Episode 10: The Immunotherapy Patient Perspective

    We sat down with journalist Mary Elizabeth Williams, one of the first patients treated with combination immunotherapy, to discuss her experience as an IO patient and how to bridge communication gaps among patients, doctors, and researchers.

  • [PODCAST] Episode 8: Immunotherapy and Emergency Medicine

    Learn why a trip to the emergency department is different for patients who receive immunotherapy for cancer, what information helps ED clinicians, and what busy emergency department providers need to know about immune-related adverse events.

  • Facilitating Access to Cancer Immunotherapies
    Access to new cancer immunotherapies is important for patients in an increasing number of cancers. Integrating costly paradigm-changing treatments into practice requires expertise from the oncology pharmacist working closely with administration, oncology nursing, and new team members such as oncology financial navigators.
  • Communication: Key to Addressing Toxicity and Recurrence Risks
    By Mark B. Faries, MD

    Immuno-oncology (IO) has radically altered the patient care paradigm. One of most important changes attributed to IO is improvement in outcomes and lengthening of survival. This good news comes with multiple challenges, not least of which is the need for new and better communication and coordination among multiple specialties over time. 

From Oncology Issues

  •  Virtual Toxicity Team Cleveland Clinic
    This article explores how Cleveland Clinic is taking a unique approach to recruiting specialists outside the field of oncology to participate in immunotherapy multispecialty immune-related adverse events (irAE) tumor boards.
  •  Virtual Toxicity Team Jefferson Health
    This article explores how Jefferson Health is taking a unique approach to recruiting specialists outside the field of oncology to participate in an Immuno-oncology Working Group.
  •  Virtual Toxicity Team Johns Hopkins University
    This article explores Johns Hopkins University’s unique approach to recruiting specialists outside the field of oncology to participate in its virtual immune-related Toxicity Team.
  • Elevating Survivorship: Results from Two National Surveys
    In order to explore experiences and needs concerning cancer survivorship from both the provider and the patient perspectives, ACCC and NCCS partnered to field two online surveys to oncology providers and cancer survivors, respectively.
  • A Physician Champion Takes a Practice-Based Immunotherapy Program to the Next Level
    Tracy Virgilio, RN, MSN, OCN
    Early symptom management is key to improving quality of life for patients with cancer, and proactive monitoring delivers unparalleled survival advantage while decreasing emergency visits and admissions. However, immunotherapies require special attention and procedures. Sidney Kimmel Cancer Center earned a 2018 ACCC Innovator Award for their immunotherapy triage algorithms, which provide non-oncology physicians and nurses with the tools to manage IO patients and prevent unnecessary admissions.
  •  Immuno-Oncology: Breaking Barriers, Exploring Solutions, Improving Patient Care
    The ACCC Immuno-Oncology Institute developed a multidisciplinary curriculum workshop bringing together faculty experienced in delivery of immunotherapy with cancer program staff in the earlier stages of IO integration. Over the past two years, these IO Visiting Experts Programs were hosted by ACCC Cancer Program Members nation-wide.
  •  Best Practices for Implementing Cancer Immunotherapy in the Community
    The Association of Community Cancer Centers (ACCC) recently hosted live continuing medical education (CME)-certified learning workshops at two community cancer programs to review current barriers to immunotherapy implementation in the community setting. During the workshops, an expert faculty panel engaged participants in discussion on the challenges that they may face as they integrate immunotherapy into their clinical practice, as well as practical solutions and strategies they can apply to overcome these barriers. This article summarizes the guidance and information provided by the faculty on the various issues raised during the workshop discussions.
  •  Highlights from ASCO 2018
    By Cary A. Presant, MD, FACP, FASCO
    ASCO 2018 offered a wealth of new data that will continue to transform clinical practice and cancer program development. Most important, implementation of the scientifi c advances we learned at ASCO 2018 will improve the length and quality of life of our cancer patients.
  •  Turning on the Light Switch
    By Ann McGreal, RN
    Discover how 2017 ACCC Innovator Award winner Advocate Medical Group developed and implemented an immunotherapy program, lessons learned, and tools created to educate staff and patients.
  •  Best of ASCO 2017
    Cary A. Presant, MD, FACP, FASCO
    ASCO 2017 was filled with new information and long lines as 39,000 oncologists worldwide came together to hear the latest advances in cancer care.
  •  Real-World Experiences in Immunotherapy Delivery
    The ACCC education project, “Real-World Experiences in Immunotherapy Delivery,” addresses some of the practical issues that cancer programs must navigate to provide immunotherapy safely and effectively in their own communities.
  •  Advancing Immuno-Oncology in the Community Setting
    Steven Powell, MD
    As cancer treatment evolves with the emergence of genomics, personalized therapies, and immunotherapies, care delivery must also transform.